Detalhe da pesquisa
1.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(5): 655-663, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32251621